Background First-line maintenance erlotinib in patients with locally advanced or metastatic
nonsmall cell lung cancer (NSCLC) has demonstrated significant overall survival and …

Background Platinum-doublet, first-line treatment of locally advanced or metastatic non-
small cell lung cancer (NSCLC) is limited to 4–6 cycles. An alternative strategy used to …

Maintenance therapy, commenced immediately after the completion of first-line
chemotherapy, is a promising strategy for improving treatment outcomes in patients with non …

Erlotinib and pemetrexed were approved by the European Medicines Agency for first-line
maintenance treatment of patients with locally advanced or metastatic non-small-cell lung …

Introduction The cost-effectiveness of first-line tyrosine kinase inhibitor therapy in epidermal
growth factor receptor gene (EGFR)-mutated advanced-stage non–small cell lung cancer …

Several clinical and biological parameters are known to influence the efficacy of second-line
erlotinib therapy for nonsmall cell lung cancer (NSCLC), but their medico-economic impact …

Purpose The controlled phase III trial SATURN demonstrated that maintenance therapy with
erlotinib after the first-line platinum-based chemotherapy prolonged progression-free …

The first-line treatment of advanced non-small-cell lung cancer (NSCLC) generally consists
of a maximum of six cycles of platinum-based doublet chemotherapy followed by …

Background In the placebo-controlled phase III SATURN study, maintenance erlotinib after
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …

Background First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …